ArticleClinical drug investigation2023

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.

Pedro Herranz-Pinto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.